Influence of dopamine agonist pramipexole (mirapex) on tremor, cognitive and affective impairment in patients with Parkinson's disease

Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova

Volumn 109, Issue 8, 2009, Pages 36-41

  Levin, O S ^a   Nesterova, O S ^a   Otcheskaya, O V ^a   Zhuravleva, E Yu ^a   Artemova, I Yu ^a   Khozova, A A ^a   Ismailov, A M ^a   Lisenker, L N ^a   Vdovichenko, T V ^a   Rotor, L D ^a   Ganzhula, P A ^a   Ivanov, A K ^a   Boyko, A N ^a  

^a NONE

Author keywords

Depression; Pramipexole; Tremor

Indexed keywords

BENZOTHIAZOLE DERIVATIVE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; PRAMIPEXOL;

ADULT; AFFECT; AGED; ARTICLE; COGNITION; COGNITIVE DEFECT; COMPARATIVE STUDY; DRUG EFFECT; DRUG POTENTIATION; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; MOOD DISORDER; PARKINSON DISEASE; PATHOPHYSIOLOGY; PHYSIOLOGY; TREATMENT OUTCOME; TREMOR;

ADULT; AFFECT; AGED; BENZOTHIAZOLES; COGNITION; COGNITION DISORDERS; DOPAMINE AGONISTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MOOD DISORDERS; PARKINSON DISEASE; RECEPTORS, DOPAMINE D2; TREATMENT OUTCOME; TREMOR;

EID: 70349106866     PISSN: 19977298     EISSN: 19977298     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Spanish Source.
2. Spanish Source.
3. Spanish Source.
4. Spanish Source.
5. Spanish Source.
6. Spanish Source.
7. Spanish Source.
8. Alexopoulos G. The depression-executive dysfunction syndrome of late life. Am J Geriat Psychiat 2001;9:22-29.
9. Almeda S., Ranjith G. Using pramipexole in neuropsychiatry: a cautionary note. J Neuropsychiat Clin Neurosci 2006;18:556-557.
10. Bain P.G., Findley L.J. Assessing tremor severity. London: Smith Gordon 1993; 27.
11. Barone P., Scarzella L., Marconi R. et al. Pramipexole versus sertraline in the treatment of depression in Parkinson disease. J Neurol 2006;253:555-561.
12. Biglan K.M., Holloway R.H., McDermott M.P. et al. Risk factors for somnolence, edema and hallucinations in early Parkinson disease. Neurology 2007;69:187-195.
13. Brooks D.J. Dopamine agonists: their role in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiat 2000;68:685-689.
14. Brooks R., Rabin R., De Charro F. The measurement and valuation of health status using EQ-5D. Dodrechn: Kluwer Academic Publishers 2003; 303.
15. Brusa L., Bassi A., Stefani A. et al. Pramipexole in comparison to L-dopa: a neuropsychological study. J Neural Transm 2003;110:373-380.
16. Constantinescu R., Romer M., McDermott M.P. et al. Impact of pramipexole on the onset oof levodopa-related dyskinesias. Mov Dis 2007;22:1317-1319.
17. DeBattista C., Solvason H.B., Breen J. et al. Pramipexole in the augmentation of a selective serotonin reuptake inhibitor in the treatment of depression. J Clin Psychopharmacol 2000;20:274-275.
18. Fahn S., Elton R.L. Unified rating scale for Parkinson's disease. In: S. Fahn, C.D. Marsden (eds). Recent developments in Parkinson's disease. Florham Park. New York: Macmillan 153-163.
19. Folstein M.F., Folstein S.E., McHugh P.R. Mini-mental status. J Psychiat Res 1975;12:189-196.
20. Gibb W., Lees A. Relevance Lewy body pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiat 1988;51:745-752.
21. Guttman M., and the International Pramipexole-Bromocriptine Study Group. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. Neurology 1997;49:1060-1065.
22. Hauser R.A., McDermott M.P., Messing S. et al. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol 2006;63:1756-1760.
23. Hauser R.A., Rascol O., Korczyn A.D. et al. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov Dis 2007;22:1458-1463.
24. Hoehn M., Jahr M.D. Parkinsonism: onset, progression and mortality. Neurology 1967;17:5:427-442.
25. Holloway R.G., Shoulson I., Fahn S. et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004;61:1044-1053.
26. Hubble J.P., Koller W.C., Cutler N.R.,et al. Pramipexole in patients with early Parkinson's disease. Clin Neuropharmacol 1995;18:338-347.
27. Jenkinson C., Fitzpatrick R., Peto V. The PDQ-8: Development and validation of a short-form Parkinson's disease questionnaire. Psychol Health 1997;12:805-814.
28. Kleiner-Fisman G., Fisman D. Risk factors for the development of pedal edema in patients using pramipexole. Arch Neurol 2007;64:820-824.
29. Lemke M.R., Brecht H.M., Koester J. et al. Anhedonia, depression and motor functioning in Parkinson's disease during treatment with pramipexole. J Neuropsychiat Clin Neurosci 2005;17:214-220.
30. Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: Results of a double-blind, placebo-controlled, parallel-group study. Neurology 1997;49:162.
31. Montgomery S.A., Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiat 1979;134:382-389.
32. Moller J.C., Oertel W.H., Koster J. et al. Long-term efficacy and safety of pramipexole in advanced Parkinson;s disease: results from a European multicenter trial. Mov Dis 2005;20:602-610.
33. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson's disease. A randomized controlled trial. JAMA 2000;284:1931-1938.
34. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects on pramipexole vs levodopa on Parkinson disease progression. JAMA 2002;287:1653-1661.
35. Pinter M.M., Pogarell O., Oertel W.H. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study. J Neurol Neurosurg Psychiat 1999;66:436-441.
36. Pogarell O., Gasser T., Van Hilten J.J. et al. Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study. J Neurol Neurosurg Psychiat 2002;72:713-720.
37. Rektorova I., Rektor I., Bares M. et al. Pramipexole and pergolide in the treatment of depression in Parkinson disease. Eur J Neurol 2003;10:399-406.
38. Schapira A.H. Treatment options in the modern management of Parkinson disease. Arch Neurol 2007:64:1083-1088.
39. Shannon K.M., Bennett J.P., Friedman J.H. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. Neurology 1997;49:724-728.
40. Shulman L.M., Minagar A., Rabinstein A. et al. The use of dopamine agonists in very elderly patients with Parkinson's disease. Mov Dis 2000;15:664-668. (Pubitemid 30479618)
41. Yesavage J.A., Brink T.L., Rose T.L. et al. Development and valodationa geriatric depression screening scale. J Psychiat Res 1982;17:37-49.